OncView™ Podcast: Management of Relapsed/Refractory Follicular Lymphoma

News
Podcast

This special edition of the “Oncology Peer Review On-The-Go” podcast details treatment options and considerations for relapsed/refractory follicular lymphoma.

As part of its OncView™ video series, CancerNetwork® spoke with Sameh Gaballa, MD, of the Moffit Cancer Center, about current and future treatment options and considerations for patients with relapsed/refractory follicular lymphoma (R/R FL).

In the video series, Gaballa discussed the following:

To watch more videos in CancerNetwork®’s OncView™ series, visit cancernetwork.com/oncview.

Recent Videos
The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.
This series features 2 KOLs.
This series features 2 KOLs.
relapsed or refractory mantle cell lymphoma, glofitamab, Obinutuzumab, phase 1/2 study, NCT03075696, Tycel J. Phillips, MD
This series features 2 KOLs.
This series features 2 KOLs.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
Related Content
Creating Confidence While Climbing the Ranks in the Lymphoma Field

Creating Confidence While Climbing the Ranks in the Lymphoma Field

Ariana Pelosci
July 25th 2024
Article

“Sometimes you have to be a little more assertive and a little louder, and you have to step up to the front,” Julie M. Vose, MD, MBA, said.

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Overcoming Physical and Social Barriers in the Lymphoma Field

Julie M. Vose, MD, MBA;Avyakta Kallam, MD
July 15th 2024
Podcast

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

FDA Approval Alert: Liso-Cel in Relapsed/Refractory Mantle Cell Lymphoma

FDA Approval Alert: Liso-Cel in Relapsed/Refractory Mantle Cell Lymphoma

ONCOLOGY Staff
July 12th 2024
Article

Michael Wang, MD, spoke about the recent liso-cel approval in mantle cell lymphoma and the TRANSCEND trial.

Bispecific antibodies including epcoritamab have “a lot of potential for upward mobility” in lymphoma, according to Tycel Phillips, MD.

Epcoritamab Approval Expands Bispecific Use in Follicular Lymphoma

Tycel Phillips, MD
July 8th 2024
Podcast

Bispecific antibodies including epcoritamab have “a lot of potential for upward mobility” in lymphoma, according to Tycel Phillips, MD.

EU’s CHMP Recommends Epcoritamab Approval in R/R Follicular Lymphoma | Image Credit: © Kateryna_Kon - stock.adobe.com.

EU’s CHMP Recommends Epcoritamab Approval in R/R Follicular Lymphoma

Russ Conroy
June 28th 2024
Article

The European Commission is expected to decide on approving epcoritamab in relapsed/refractory follicular lymphoma later in 2024.

Findings from the EPCORE NHL-1 trial support the FDA approval of epcoritamab in relapsed/refractory follicular lymphoma.

FDA Grants Accelerated Approval to Epcoritamab in R/R Follicular Lymphoma

Roman Fabbricatore;Russ Conroy
June 26th 2024
Article

Findings from the EPCORE NHL-1 trial support the FDA approval of epcoritamab in relapsed/refractory follicular lymphoma.